Company intelligence / Profile preview

Saile

Shanghai, Shanghai Shi, Chinasailes.com ↗

Ownership: Private
Development stage: Commercial

Overview

Saile Pharmaceutical Technology is a private joint venture company based in Shanghai, China, focused on small molecule drugs targeting endocrinology/metabolic and nervous system/cardiovascular diseases. Its pipeline includes generic or combination products such as nifedipine and sitagliptin phosphate/metformin hydrochloride at late clinical or regulatory stages. No novel clinical results are reported publicly as of January 2025.

Therapeutic areas: EndocrinologyCardiovascularNeurology
Modalities: Small molecule drug
Industry: Biotech

Beyond the preview

Go deeper on Saile.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saile.

Explore the full profile